• Roche AG, of Basel, Switzerland, said it started a Phase I trial of an investigational molecule designed to address the cognitive and behavioral deficits associated with Down syndrome by targeting the gamma-amino butyric acid system. The study will recruit adults with Down syndrome between the ages of 18 and 30, and will assess the drug's safety and tolerability.